At the same time, we are in the very final stages of manufacturing technology transfer to Operon in Spain. The first mass production version of our COVID-19 ART, a pre-requisite for finalising clinical trials and regulatory approvals, will be produced in Spain in just a few days’ time.
Our saliva test development work continues as a highest priority focus. We continue to be encouraged by the results we are seeing, which is helping to refine our lysis buffer formulation. We are confident that saliva will be one of the sample types that can be utilised within our COVID-19 ART .
Saliva test seems to be on the cards and turned into their highest focus.
This is extremely encouraging !
We are also in the last stages of clinical trials and moving already through regulatory
approvals.
Market will wake up to this shortly
all IMO
Ann: Quarterly Activities Report, page-2
Add ADO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.1¢ |
Change
-0.002(6.67%) |
Mkt cap ! $51.83M | |||
| Open | High | Low | Value | Volume |
| 2.3¢ | 2.3¢ | 2.1¢ | $9.62K | 435.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 3095470 | 2.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.2¢ | 620879 | 1 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
2.1¢ |
Change
-0.002 ( 4.55 %) |
||||
| Open | High | Low | Volume | ||
| 2.3¢ | 2.3¢ | 2.1¢ | 732014 | ||
| Last updated 15.59pm 14/06/2024 ? | |||||
| ADO (ASX) Chart |